By comparison, median IC50 values of 76.24 ng/ml and 10.86 ng/ml, respectively, were displayed by in-house-generated recombinant sifalimumab and rontalizumab, two anti-IFN mAbs used in clinical trials for systemic lupus erythematosus patients (Table S4). The gene discussed is IFNA1; the disease is systemic lupus erythematosus.